Development of transcriptomic tools for predicting the response to individual drug of the mFOLFIRINOX regimen in patients with metastatic pancreatic cancer.

Fiche publication

Date publication

septembre 2024

Journal

Frontiers in oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PESSAUX Patrick

Tous les auteurs :
Fraunhoffer N, Teyssedou C, Pessaux P, Bigonnet M, Dusetti N, Iovanna J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39323995

Résumé

The utilization of modified FOLFIRINOX (mFFX) therapy has shown notable advancements in patient outcomes in both localized and metastatic PDAC. Nevertheless, the effectiveness of mFFX treatment comes at the cost of elevated toxicity, leading to its restriction to patients with adequate performance status. Consequently, the administration of mFFX is contingent upon patient performance rather than rational criteria. The ideal scenario would involve the ability to assess the sensitivity of each drug within the mFFX regimen, minimizing unnecessary toxicity without compromising clinical benefits.